Saturday 17 October 2026
Export ATYR’s income statement to Excel — free account
aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.17
0.01
−5.56%
Follow ATYR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
6.27 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(3.42) | — | — | — | |
P/B ratio |
0.87 | — | — | — | |
Price to Tangible BV |
0.87 | — | — | — | |
EV/Sales |
(1.50) | — | — | — | |
EV/EBITDA |
0.21 | — | — | — | |
EV/Operating CF |
0.27 | — | — | — | |
EV/FCF |
0.27 | — | — | — | |
Quick Ratio |
5.82 | 5.25 | 5.73 | 5.08 | |
Current Ratio |
5.93 | 5.30 | 5.78 | 5.12 | |
Net Debt/EBITDA |
3.34 | 5.31 | 5.87 | 5.40 | |
Debt/Assets |
0.37% | 0.28% | 0.19% | 0.05% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.87 | 1.16 | 0.91 | |
Capex/Depreciation |
0.30 | (0.58) | (0.99) | (0.28) | |
Research and Development Expense of Revenue |
11,647.37% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,528.95% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
687.89% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.95 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(115.28%) | — | — | — | |
Free Cash Flow Yield |
(90.07%) | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.13) | (0.13) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.13) | (0.13) | (0.10) | |
Cash per Share |
0.93 | 0.85 | 0.68 | 0.59 | |
Shareholders Equity per Share |
0.82 | 0.72 | 0.59 | 0.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 0.72 | 0.59 | 0.50 | |
Free Cash Flow |
(20.51) | (12.21) | (12.65) | (9.42) | |
Working Capital |
77.34 | 65.09 | 55.88 | 46.97 | |
Capital Expenditures |
(0.04) | (0.02) | (0.14) | (0.07) | |
Net Current Asset Value |
66.41 | 54.52 | 45.66 | 37.13 | |
EV/EBIT |
0.21 | — | — | — | |
Capex to Sales |
0.19 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
1.44 | 1.30 | 0.73 | 0.46 | |
Average Payables |
4.01 | 4.11 | 2.14 | 3.56 | |
Average Assets |
99.13 | 94.92 | 88.45 | 85.68 | |
Average Common Equity |
72.59 | 68.56 | 66.30 | 61.63 |
Columns are period end dates